Our professionals
Partner
Ana Cândida Sammarco
Areas of expertise
Experience
Leading our Life Sciences & Healthcare practice, Ana works with various Brazilian government agencies, notably the National Health Surveillance Agency (Anvisa) and the National Supplementary Health Agency (ANS). She counsels and litigates on behalf of domestic and foreign clients on regulatory, transactional and contractual matters. Ana previously practiced at the New York office of Linklaters LLP, and is part of the São Paulo Bar Association’s (OAB-SP) Special Committee on Health Law and Special Committee on Medical and Health Law.
Education
Bachelor of Laws – Universidade Presbiteriana Mackenzie;
Master of Laws (LL.M.) – University of Miami;
Extension course in Business Negotiaion – Harvard Law School, Cambridge;
Extension course in Business Law – Escola de Formação da Sociedade Brasileira de Direito Público (SBDP).
Recognitions
Chambers Brazil – Life Sciences (2021 – 2024) and Healthcare: Regulatory (2021 – 2024);
The Legal 500 – Life Sciences: Leading Partners (2022 – 2025);
Análise Advocacia – Regulatory (2019 – 2024), Chemical & Petrochemical (2019 – 2021), Pharmaceutical (2023 – 2024) and São Paulo (2019 – 2024);
Análise Advocacia Mulher – Regulatory (2021 – 2024), Chemical & Petrochemical (2021 – 2022, 2024), Pharmaceutical (2023 – 2024) and São Paulo (2021 – 2022);
Lexology Index Brazil: Thought Leaders Life Sciences (2021 – 2024), Life Sciences (2024);
Lexology Index Global: Healthcare (2020 – 2021), Life Sciences: Regulatory (2021 – 2024) and Thought Leaders Global Elite: Life Sciences (2023).
Anvisa approves new resolution regarding simplified marketing authorization in Brazil
Subjects:
Anvisa updates clinical trial regulations
Subjects:
New regulations for partnership programs in Brazilian health: opportunities and challenges
Subjects:
New legal framework for clinical trial with human subjects approved in Brazil
Subjects:
Brazilian health agency regulates use of foreign regulatory authorities’ assessments
Subjects:
A Decade of Brazil’s Clean Companies Law: Progress and Challenges
Ever since Brazil’s Clean Companies Law (Law No. 12,846/2013) formally took effect in January 2014, the country’s corporate integrity culture has become significantly stronger. The OfÏce of the Comptroller General (CGU) has been at the forefront of this shift in its role as a regulatory enforcer for the private sector. In 2024, Brazilian agencies initiated a total of 260 enforcement proceedings against companies, which primarily involved undue advantages to government ofÏcials (the administrative offense closely related to bribery) and instances of fraud in public bids and contracts. We expect the corporate integrity landscape in Brazil to continue evolving in the wake of further regulatory changes, technological progress, and increasing transparency and corporate responsibility requirements.
Click here and read the article on The Legal Industry Reviews.
Areas of expertise
Recent Developments in Brazil’s Clinical Trial Framework
2024 presented an intensely dynamic legislative and regulatory landscape for the life sciences industry in Brazil, with important developments in several areas. Among these, Congress has finally passed a federal statute on research and trials involving human subjects. Federal Law 14,874/2024 established the National System of Ethics in Research with Human Beings (the “System”). This law regulates Research Ethics Committees (CEP) and sets parameters for protecting the rights of trial subjects and the legal responsibilities of investigators and sponsors.
Click here and read the article on The Legal Industry Reviews.
Areas of expertise
Stay in touch
Get first-hand access to legal analysis from our specialists in different sectors through texts and podcasts. Stay on top of the main issues that impact your business.
